Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the \"ARCHER\" trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
相关临床试验
9
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
22.2%
已完成
4
44.4%
招募中
2
22.2%
终止
1
11.1%
暂无批准数据
- Cardiol Therapeutics has achieved 50% patient enrollment in its pivotal Phase III MAVERIC trial evaluating CardiolRx™ for recurrent pericarditis prevention. - The trial is actively enrolling patients across more than 15 leading cardiovascular centers in the United States, with additional sites coming online in Europe and Canada. - Full enrollment of approximately 110 patients is expected by Q2 2026, with the primary endpoint being freedom from new episodes of recurrent pericarditis after six months. - CardiolRx™ demonstrated positive results in the Phase II MAvERIC-Pilot study, showing rapid reductions in pericarditis pain and inflammation with a marked decrease in recurrence events.
- Cardiol Therapeutics' Phase II ARCHER trial demonstrated that CardiolRx significantly reduced left ventricular mass and improved cardiac structure in 109 patients with acute myocarditis. - The randomized, double-blind, placebo-controlled study showed favorable trends in myocardial inflammation markers while maintaining a safe and well-tolerated profile. - Results published in ESC Heart Failure support the biological rationale for CardiolRx across inflammatory myopericardial syndromes and strengthen the ongoing Phase III MAVERIC trial in recurrent pericarditis. - The findings indicate reduced myocardial edema and inflammatory burden, changes associated with better clinical outcomes in myocarditis patients.
- Cardiol Therapeutics completed an $11 million private placement offering that extends the company's cash runway into Q3 2027 and fully funds the Phase III MAVERIC trial through FDA submission. - The ARCHER trial demonstrated significant reduction in left ventricular mass in myocarditis patients, marking the first evidence of structural and remodeling improvement in this condition. - The funding will accelerate development of next-generation therapy CRD-38 for heart failure, with partnership discussions advancing with leading pharmaceutical companies. - CardiolRx has received FDA Orphan Drug Designation for pericarditis treatment, with the company pursuing additional designation for myocarditis based on ARCHER findings.
- Cardiol Therapeutics' cannabidiol-based therapy CardiolRx failed to meet co-primary endpoints in the Phase II ARCHER trial for myocarditis, with extracellular volume reduction missing statistical significance (p=0.0538). - The company's stock dropped 20% from $1.35 to $1.07 following the trial results, despite CEO David Elsley expressing satisfaction with the outcomes. - While CardiolRx showed some cardiac improvements including significant left ventricular mass reduction, it failed to improve global longitudinal strain scores compared to placebo. - The company continues advancing its Phase III MAVERIC trial for recurrent pericarditis and plans to integrate ARCHER findings into broader clinical development strategy.
- New data published in JACC demonstrates CRD-38's ability to improve cardiac function and reduce inflammation through its unique cannabidiol-based mechanism of action. - Preclinical studies reveal CRD-38's subcutaneous administration resulted in reduced cardiac fibrosis, improved ejection fraction, and enhanced cardiac output in heart failure mouse models. - The development addresses a growing unmet need in heart failure treatment, particularly significant given the increasing prevalence of the condition due to aging populations and rising cardiovascular risk factors.
- Cardiol Therapeutics executives and board members increased their holdings after promising Phase II trial results for CardiolRx™ in recurrent pericarditis. - The MAvERIC-Pilot trial demonstrated significant reductions in pericarditis pain and C-reactive protein levels, with a favorable safety profile. - A Phase III trial is planned to evaluate CardiolRx™ in recurrent pericarditis patients after interleukin-1 blocker therapy cessation. - Insider buying included purchases by the CEO, CFO, COO, and board members, signaling confidence in the company's prospects.
- GeoVax Labs' COVID-19 vaccine candidate, GEO-CM04S1, demonstrates positive Phase 2 trial results in chronic lymphocytic leukemia (CLL). - Cardiol Therapeutics' CardiolRx shows strong Phase 2 results for recurrent pericarditis treatment, advancing to late-stage clinical trials. - Vuzix Corp. secures a major contract to supply customized waveguides to a U.S. aerospace and defense company.
- Cardiol Therapeutics is advancing its lead drug, CardiolRx™, to a Phase 3 clinical trial (MAVERIC) for patients with recurrent pericarditis at high risk of recurrence. - CardiolRx™ is uniquely positioned to address critical gaps in current treatment options for recurrent pericarditis, potentially offering a safer, more cost-effective, and disease-modifying approach. - Phase 2 trial results presented at the American Heart Association showed sustained pain reduction and decreased inflammation markers with CardiolRx™. - The FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis, potentially accelerating its path to market.
- Cardiol Therapeutics' CardiolRx demonstrated lasting improvements in pericarditis symptoms over a 26-week extension in the Phase II MAvERIC-Pilot study. - The study reported that 71% of patients remained recurrence-free when transitioned to CardiolRx monotherapy, highlighting the drug's potential effectiveness. - High tolerance levels were observed, with 89% of participants completing the study and adherence reaching 95%, supporting further clinical trials. - Anticipation is building for positive results from Cardiol’s acute myocarditis phase II study, expected by early 2025.
- Cardiol Therapeutics' CardiolRx demonstrated significant improvements in pericarditis pain and inflammation over 26 weeks in a Phase 2 trial. - The MAvERIC-Pilot study results support the advancement of CardiolRx into late-stage clinical trials, including the pivotal Phase 3 MAVERIC-3 trial. - CardiolRx was shown to be safe and well-tolerated, strengthening the case for its continued development as a treatment for recurrent pericarditis and acute myocarditis.
